Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Metastatic cancer remains an almost inevitably lethal disease,–. A better understanding of
disease progression and response to therapies therefore remains of utmost importance …

Visualization of the cellular heterogeneity and spatial architecture of the tumor
microenvironment (TME) is becoming increasingly important to understand mechanisms of …

Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …

Germline loss-of-function mutations of the VHL tumor suppressor gene cause von Hippel–
Lindau disease, which is associated with an increased risk of hemangioblastomas, clear cell …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma
(uHCC) with potential immunomodulatory effects, suggesting that its combination with …

Peritoneal metastasis is the leading cause of death for gastrointestinal cancers. The native
and therapy-induced ascites ecosystems are not fully understood. Here, we characterize …

Tumours are surrounded by a host immune system that can suppress or promote tumour
growth. The tumour microenvironment (TME) has often been framed as a singular entity …